The Efficacy And Feasibility Of Allogeneic Hematopoiet ıc Stem Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia
The refractory acute myeloid leukemia (AML) includes patients who fail standard induction chemotherapy, relapse within 6 months after first complete remission and relapse twice or more. The outcome of these patients is usually very poor with only a small proportion could be rescued by allogenic hematopoietic stem cell transplantation (alloHSCT). The aim of this study is to evaluate the efficacy and feasibility of alloHSCT in patients with refractory AML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Rafiye Ciftciler, Haluk Demiroglu, Yahya Buyukas ık, Elifcan Aladag, Salih Aksu, Ibrahim C. Haznedaroglu, Nilgun Sayınalp, Osman Ozcebe, Umit Yavuz Malkan, Hakan Goker Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants